241 related articles for article (PubMed ID: 32766830)
1. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse.
Borren NZ; Plichta D; Joshi AD; Bonilla G; Sadreyev R; Vlamakis H; Xavier RJ; Ananthakrishnan AN
Inflamm Bowel Dis; 2020 Sep; 26(10):1524-1532. PubMed ID: 32766830
[TBL] [Abstract][Full Text] [Related]
2. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.
Dawiskiba T; Deja S; Mulak A; Ząbek A; Jawień E; Pawełka D; Banasik M; Mastalerz-Migas A; Balcerzak W; Kaliszewski K; Skóra J; Barć P; Korta K; Pormańczuk K; Szyber P; Litarski A; Młynarz P
World J Gastroenterol; 2014 Jan; 20(1):163-74. PubMed ID: 24415869
[TBL] [Abstract][Full Text] [Related]
3. Exploring Predictive Biomarkers of Relapse in Ulcerative Colitis: A Proteomics Approach.
Assadsangabi A; Evans CA; Corfe BM; Lobo AJ
Inflamm Bowel Dis; 2024 May; 30(5):808-819. PubMed ID: 37889841
[TBL] [Abstract][Full Text] [Related]
4. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
5. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
[TBL] [Abstract][Full Text] [Related]
6. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
[TBL] [Abstract][Full Text] [Related]
8. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
[TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of micronutrient status in quiescent inflammatory bowel disease.
MacMaster MJ; Damianopoulou S; Thomson C; Talwar D; Stefanowicz F; Catchpole A; Gerasimidis K; Gaya DR
Clin Nutr; 2021 Jan; 40(1):327-331. PubMed ID: 32517876
[TBL] [Abstract][Full Text] [Related]
10. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12.
Däbritz J; Langhorst J; Lügering A; Heidemann J; Mohr M; Wittkowski H; Krummenerl T; Foell D
Inflamm Bowel Dis; 2013 May; 19(6):1130-8. PubMed ID: 23377171
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
13. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
14. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
15. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
[TBL] [Abstract][Full Text] [Related]
16. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.
Wagner M; Peterson CG; Ridefelt P; Sangfelt P; Carlson M
World J Gastroenterol; 2008 Sep; 14(36):5584-9; discussion 5588. PubMed ID: 18810778
[TBL] [Abstract][Full Text] [Related]
17. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
Boon GJ; Day AS; Mulder CJ; Gearry RB
World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
[TBL] [Abstract][Full Text] [Related]
18. Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.
Keshteli AH; van den Brand FF; Madsen KL; Mandal R; Valcheva R; Kroeker KI; Han B; Bell RC; Cole J; Hoevers T; Wishart DS; Fedorak RN; Dieleman LA
World J Gastroenterol; 2017 Jun; 23(21):3890-3899. PubMed ID: 28638229
[TBL] [Abstract][Full Text] [Related]
19. Can calprotectin predict relapse risk in inflammatory bowel disease?
D'Incà R; Dal Pont E; Di Leo V; Benazzato L; Martinato M; Lamboglia F; Oliva L; Sturniolo GC
Am J Gastroenterol; 2008 Aug; 103(8):2007-14. PubMed ID: 18802997
[TBL] [Abstract][Full Text] [Related]
20. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
